.png){kind=icon}
.png){kind=icon}
Return
Legumain-responsive albumin-binding prodrug enables tumor-selective drug release and immunomodulatory remodeling for enhanced antitumor efficacy in ovarian cancer
.png){kind=icon}
PRE
AI
H
Z
Y
Y
Y
Y
Y
W
Z
DOI：10.1016/j.ijpharm.2026.126954.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Albumin-binding prodrugs represent a pharmacological strategy to improve systemic stability and tumor exposure of cytotoxic agents. Legumain, an asparagine endopeptidase selectively activated in the acidic tumor microenvironment, provides a mechanism for tumor-specific prodrug activation. In this study, we developed WC10-003, a legumain-responsive albumin-binding prodrug of belotecan, and investigated its pharmacological properties and antitumor activity in ovarian cancer models.
Keywords:
albumin-binding prodrug
legumain
belotecan
ovarian cancer
tumor microenvironment
Journal
IF:
5.2
Papers:
2.2W
Citations:
6.7W
Organization
Cited Papers